Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
Authors:
- 7 July 2010
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 67 (4) , 945-954
Abstract
Purpose Aurora A kinase is critical in assembly and function of the mitotic spindle. It is overexpressed in various tumor types and implicated in oncogenesis and tumor progression. This trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of MLN8054, a selective small-molecule inhibitor of Aurora A kinase. Methods In this first-in-human, dose-escalation study, MLN8054 was given orally for 7, 14, or 21 days followed by a 14-day treatment-free period. Escalating cohorts of 3–6 patients with advanced solid tumors were treated until DLT was seen in ≥2 patients in a cohort. Serial blood samples were collected for pharmacokinetics and skin biopsies were collected for pharmacodynamics. Results Sixty-one patients received 5, 10, 20, 30, or 40 mg once daily for 7 days; 25, 35, 45, or 55 mg/day in four divided doses (QID) for 7 days; or 55, 60, 70, or 80 mg/day plus methylphenidate or modafinil with daytime doses (QID/M) for 7–21 days. DLTs of reversible grade 3 benzodiazepine-like effects defined the estimated MTD of 60 mg QID/M for 14 days. MLN8054 was absorbed rapidly, exposure was dose proportional, and terminal half-life was 30–40 h. Three patients had stable disease for >6 cycles. Conclusions MLN8054 dosing for up to 14 days of a 28-day cycle was feasible. Reversible somnolence was dose limiting and prevented achievement of plasma concentrations predicted necessary for target modulation. A recommended dose for investigation in phase 2 trials was not established. A second-generation Aurora A kinase inhibitor is in development.Keywords
This publication has 30 references indexed in Scilit:
- Aurora kinase inhibitors in preclinical and clinical testingExpert Opinion on Investigational Drugs, 2009
- Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast CancerClinical Cancer Research, 2008
- Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer PatientsClinical Cancer Research, 2007
- MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to AneuploidyMolecular and Cellular Biology, 2007
- Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseProceedings of the National Academy of Sciences, 2007
- Biological Characteristics in Bladder Cancer Depend on the Type of Genetic InstabilityClinical Cancer Research, 2006
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora KinasesMolecular and Cellular Biology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancersThe EMBO Journal, 1998